ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$8.75
0.03 (0.34%)
▲
5d:
+5.29%
30d:
+10.48%
90d:
+5.55%
BUY
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.5/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ADMA shows positive signals but monitor for confirmation. Market pricing in 11.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ADMA shows positive signals but monitor for confirmation. Market pricing in 11.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.45
Based on 13.3% avg growth
INTRINSIC VALUE TODAY
$14.56
39.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $8.75, which is considered extended relative to its 30-day fair value range of $7.97 to $8.60. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.8) compared to its historical average (12.7). Remarkably, the market is currently pricing in an annual earnings decline of 11.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $8.17, while resistance sits at $9.04.
Market Sentiment: ADMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.60 (+101.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $8.17, while resistance sits at $9.04.
Market Sentiment: ADMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.60 (+101.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.97 -
$8.60
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 101.1% below Wall St target ($17.60)
Trading Range Analysis
30-Day Trading Range
$7.97 -
$8.60
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.17
Resistance Level
$9.04
Current Trend
Strong Downtrend
Technical data as of
Jun 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.77
Wall Street Target
$17.60
(+101.1%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
32.4%
Valuation Discount vs History
-11.7% cheaper
PE vs Historical
8.8 vs 12.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.7%
(market-implied from PE analysis)
1-Year Target
$7.87
(-10%)
2-Year Target
$7.09
(-19%)
3-Year Target
$6.38
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→13)
$9.24
(+6%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 22.6%)
$40.08
(+358%)
Base:
(SPY PE: 8.8, Growth: 22.6%)
$16.14
(+85%)
Bear:
(PE: 7.5, Growth: 22.6%)
$13.72
(+57%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 12.82 | Current EPS (TTM): $0.68
Bull Case
$14.07
(+61%)
Analyst growth 46.7%, PE expands to 14.1
Base Case
$12.79
(+46%)
Market implied 46.7%, PE stable at 12.8
Bear Case
$5.93
(-32%)
Severe decline -20.0%, PE contracts to 10.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.8 to 12.7
Stabilization Target:
$12.67
(+44.8%)
PE Expansion Potential:
+44.8%
Share & Embed Analysis
Last updated: June 28, 2026 1:02 PM ET
Data refreshes hourly during market hours. Next update: 2:02 PM
Data refreshes hourly during market hours. Next update: 2:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 60 BUY |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
